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Abstract
Neuropathic pain is a severe diabetes complication and its treatment is not satisfactory. It is
associated with neuroinflammation-related events that participate in pain generation and
chronicization. Prokineticins are a new family of chemokines that has emerged as critical
players in immune system, inflammation and pain. We investigated the role of prokineticins
and their receptors as modulators of neuropathic pain and inflammatory responses in exper-
imental diabetes. In streptozotocin-induced-diabetes in mice, the time course expression of
prokineticin and its receptors was evaluated in spinal cord and sciatic nerves, and corre-
lated with mechanical allodynia. Spinal cord and sciatic nerve pro- and anti-inflammatory
cytokines were measured as protein and mRNA, and spinal cord GluR subunits expression
studied. The effect of preventive and therapeutic treatment with the prokineticin receptor
antagonist PC1 on behavioural and biochemical parameters was evaluated. Peripheral
immune activation was assessed measuring macrophage and T-helper cytokine produc-
tion. An up-regulation of the Prokineticin system was present in spinal cord and nerves of
diabetic mice, and correlated with allodynia. Therapeutic PC1 reversed allodynia while pre-
ventive treatment blocked its development. PC1 normalized prokineticin levels and pre-
vented the up-regulation of GluN2B subunits in the spinal cord. The antagonist restored the
pro-/anti-inflammatory cytokine balance altered in spinal cord and nerves and also reduced
peripheral immune system activation in diabetic mice, decreasing macrophage proinflam-
matory cytokines and the T-helper 1 phenotype. The prokineticin system contributes to
altered sensitivity in diabetic neuropathy and its inhibition blocked both allodynia and inflam-
matory events underlying disease.
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Introduction
Although the number of available agents to manage diabetes continues to rapidly expand, the
treatment of diabetes complications remains a substantial challenge.
Diabetic neuropathy is one of the most frequent complications in diabetes mellitus [1].
Patients with diabetic neuropathy experience different forms of paraesthesia, hyperalgesia
and allodynia [2]. Many drugs are used for treating neuropathic pain (NP), but their effec-
tiveness is limited because of insufficient efficacy and side effects [3,4]. Recently, we and oth-
ers have demonstrated that pro- and anti-inflammatory cytokines produced by immune cells
as well as by glia and microglia in nerve and spinal cord are common denominators in NP
[5,6]. These start a cascade of neuroinflammation-related events that may maintain and
worsen the original injury, participating in pain generation and chronicization [7–9]. The
recently identified prokineticin system, which belongs to a new family of chemokines, has
been recognized as a regulator at cross roads of inflammation and NP. The prokineticin 2
(PROK2 or mammalian Bv8), displays a major role in triggering inflammatory pain acting
on two G-protein coupled receptors, the prokineticin receptor 1 (PKR1) and the prokineticin
receptor 2 (PKR2) [10,11] localized in regions of the nervous system related with pain, both
on neurons and glia [12]. PROK2 is also an important modulator of immune responses.
Immune cells express PKRs and PROK2 exerts chemotactic activities, induces a proinflam-
matory macrophage phenotype and skews the Th1/Th2 balance to Th1 [13–15]. We have
recently demonstrated that the block of this system with a specific receptor antagonist pro-
vides an efficacious control of development and maintenance of inflammatory pain and of
NP derived from traumatic nerve lesion [12,16,17].
Considering that prokineticins and their receptors are involved in nociception, immunoreg-
ulation and inflammation, they appear as candidates for controlling pain, inflammation and
neuroinflammation in diabetes. The objectives of the present study are to identify the role of
PKs system in the streptozotocin model of diabetes neuropathy in mouse, investigating its
involvement in allodynia, in neuronal alterations measuring NMDA receptors in spinal cord as
well as by evaluating cytokine levels in the main tissue stations involved in nociception trans-
mission and in peripheral immune responses. The results obtained suggest that the pharmaco-
logical modulation of the prokineticin system may be an innovative approach to control
diabetes complications.
Material and Methods
Animals and Treatments
All animal care and experimental procedures complied with the International Association for
the Study of Pain and European Community (E.C.L358/118/12/86) guidelines and were
approved by the Animal Care and Use Committee of the Italian Ministry of Health (Permission
21/2014). All efforts were made to minimize animal suffering and to reduce the number of ani-
mals used.
Studies involving animals are reported in accordance with the ARRIVE guidelines for
reporting experiments involving animals [18]. A total of 140 animals were used in the experi-
ments described here.
C57BL/6J male mice weighing 20–25 g, 9 weeks old (Harlan Laboratories, Italy) were
housed with light/dark cycles of 12 hours, temperature of 22±2°C, humidity of 55±10%, food
and water ad libitum.
Diabetes was induced in mice by intraperitoneal (i.p.) administration of Moderate Low
Doses of streptozotocin (MLD-STZ) (80 mg/ kg once daily for three consecutive days) [19]
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(Sigma Aldrich, Italy), in citrate buffer 0.1 M, pH 4.55. Control mice were injected with vehicle
(citrate buffer).
Tail-vein blood glucose concentration was assessed using a glucometer (GLUCOCARD G+
meter, Menarini diagnostics, Italy). Animals with blood glucose values above 250 mg/dl were
considered diabetic.
The PKR antagonist PC1, a triazine-guanidine compound [20], was dissolved in sterile
saline and used at the dose of 150 μg /kg [21].
Different treatment protocols were applied.
1. The effect of a single bolus of PC1 was studied inMLD-STZmice 21 days after diabetes induc-
tion evaluating the responses to mechanical stimuli 30, 60, 120 and 240 minutes after PC1.
2. Therapeutic protocol: animals were subcutaneously injected with PC1 or saline twice-daily
for 14 consecutive days starting 21 days after MLD-STZ, when they were already hypergly-
caemic and neuropathic.
3. Preventive protocol: animals were treated with PC1 or saline at the same time of STZ
(day 0), i.e. when hyperglycaemia and mechanical allodynia had not yet developed.
Mechanical Allodynia
Mechanical allodynia was monitored evaluating the mechanical touch sensitivity through a
blunt probe (Von-Frey filament, 0.5 mm diameter) on the mid plantar surface of the hind paw,
using the Dynamic Plantar Aesthesiometer (Ugo Basile, Italy) [22]. Responses to mechanical
stimuli (paw withdrawal thresholds, PWT) were measured before neuropathy induction (T0),
and weekly after MLD-STZ on both hind paws by researchers who were blind to treatments. In
all experiments, in order to avoid the evaluation of potential acute effect of the antagonist on
nociceptive thresholds, behavioural testing was performed 12–15 hours after the last drug
administration and the following PC1 administration was immediately performed after the
pain behaviour assessment.
Tissue Sampling and Preparation
Mice were killed by CO2 inhalation for spinal cord (L4-L6), sciatic nerves and pancreas dissec-
tion. Tissues were immediately frozen in liquid nitrogen and conserved at -80°C until use.
Spleens and peritoneal macrophages were also collected.
In all the experiments, last drug administration was performed in the evening, and tissues
collected the following morning, i.e. 12–15 hours after the last PC1 administration.
Measurement of IL-1β and IL-10 in Sciatic Nerve, Spinal Cord and
Pancreas
Sciatic nerves and spinal cord samples were homogenized in 0.3 ml of ice-cold phosphate-buff-
ered saline containing a protease inhibitor cocktail (lysis buffer) (Roche Diagnostics, Italy).
Pancreatic tissues were homogenized in 2 ml of the same lysis buffer. Samples were centrifuged
at 1000 g for 15 min at 4°C and supernatants collected to measure cytokines levels and total
protein content (Lowry’s method).
Measurement of GluR subunits in Spinal Cord
Nine mice/group were used for these experiments. Spinal cords from 3 mice belonging to the
same treatment groups were pooled, and the experiments repeated twice.
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Samples were homogenized using a potter in Tris-HCl buffer (50mM Tris, 120 mMNaCl,
5mM KCl, 2.5 mM, 1mMMgCl2, pH 7), washed once by centrifugation (1h; 25000g) and then
resuspended in the proper volume of the same buffer containing a 10 μg/ ml mixture of each of
the following protease inhibitors: leupeptin, bestatin, pepstatin A and aprotinin.
Total protein content was evaluated by using BCA protein assay (Pierce Chemical, Rock-
ford, IL).
Cell Sampling and Stimulation for Cytokine Assay
Macrophages. Macrophage collection was performed at the end of therapeutic PC1 treat-
ment 35 days after MLD-STZ injections. At this time point mice were killed and peritoneal
cells (PECs) were harvested in RPMI 1640 medium (Sigma-Aldrich) plus 10% FCS. Cell viabil-
ity was checked by the Trypan blue exclusion test. Turk solution was used to discriminate
nuclei and on the basis of their morphology, cells were counted.
The cells obtained from mice belonging to the same treatment groups were pooled.
PECs were diluted in collection medium at the final concentration of 1x106/ml, and 1 ml/
well aliquots were dispensed into 24-well culture plates.
Isolation and purification of macrophages were carried out by 2 hours of adherence to
plates. As previously reported [23], this procedure produces a population of macrophages with
a 90% purity. Non-adherent cells were removed, and adherent cells washed twice with PBS
solution and incubated with or without 1 μg/ ml LPS for IL-1β and IL-10 stimulation. The
stimulus was added to the macrophage cultures in a final volume of 1 ml/well in RPMI 1640
plus 10% FCS, 1% glutamine, 2% streptomycin solution and 0,1% 2-mercaptoethanol (com-
plete RPMI).
After 24 hours of culture at 37°C in 5% CO2 and 95% air, the supernatant was collected and
stored frozen at -80°C for cytokine evaluation.
Splenocytes. Spleen cell collection was performed at the end of therapeutic PC1 treatment
35 days after MLD-STZ injections.
At this time point mice were killed and their spleens rapidly and aseptically removed. Sple-
nocytes were spilled out from an incision on spleen cuticle made with 20-gauge needles,
adjusted in 24-well plates at the final concentration of 4x106 cell/ ml of culture medium
(complete RPMI, i.e. RPMI 1640 supplemented with 10% FCS, 1% glutamine, 2% antibiotics
and 0.1% 2-mercaptoethanol) and incubated at 37°C in 5% CO2 and 95% air with or without
10 μg/ ml Concanavalin A (ConA) for Th1 and Th2 cytokine stimulation. The stimulus was
added to the cell cultures in a final volume of 1 ml/well in complete RPMI.
After 24 (in the case of IFN-γ and IL-2) or 48 hours (in the case of IL-4 and IL-10) of cul-
ture, times of maximum cytokines release [23–25], the supernatant was collected and stored
frozen at -80°C for cytokine assay.
In order to evaluate the T-helper (Th)1/Th2 balance, the IFN-γ/IL-4 ratio was calculated for
each mouse and calculated by setting IFN-γ/IL-4 ratio of the control as 100%.
Real Time PCR
Total RNA was isolated from sciatic nerves and the lumbar spinal cords using Trizol1
reagent (Trifast Eurogold1, Euroclone, Italy) according to manufacturer’s instructions and
re-suspended in 10–20 μl of RNases-free water. All procedures were performed as previously
described in details [12,22]. Specific TaqMan probe/primers for mouse Prokineticin 2
(Prok2 Mm 01182450_g1), Prokineticin receptors (Prokr1 Mm00517546_m1; Prokr2
Mm00769571_m1), interleukins (IL-1βMm00434228_m1; IL-10 Mm00439616_m1) and
glyceraldehydes-3-phosphate dehydrogenase (GAPDHMm99999915_g1) were purchased
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from Applied Biosystems. Threshold cycle numbers (Ct) of the specific gene of interest and
the endogenous control gene GAPDH were determined by ABI PRISM 7000 Sequence
Detection System.
The Ct value of the specific gene of interest was normalized to the Ct value of the endoge-
nous control, GAPDH, and the comparative Ct method (2−ΔΔCt) was then applied using con-
trol/ non diabetic group as calibrator.
ELISA
Cytokine concentration was determined using ultra-sensitive ELISA kits according to the man-
ufacturer’s instruction. DuoSet1 ELISA development system s for mouse IL-1β, IL-2, IFN-γ
and IL-4 were purchased from R&D Systems (Minneapolis, USA) while mouse IL-10 ELISA
Ready-SET-Go from eBioscience (San Diego, CA). Cytokine concentrations were reported as
pg cytokine/ mg total protein content in spinal cord, sciatic nerve and pancreas. Cytokine pro-
duction by macrophages and splenocytes was reported as concentrations in culture media of
stimulated cultures.
Plasma Insulin levels were determined using a specific ELISA kit for mouse (Mercodia,
Uppsala, Sweden)
Western Blot
Antibody production and characterization. We used affinity-purified, subunit-specific
polyclonal antibodies (Abs), produced in rabbit against peptides derived from the C-terminal
(COOH), N-terminal (NH) of mouse and AMPAR GluA1 and GluA2/3 subunits. The Ab
against the GluA2/3 subunit was directed against the C-terminus peptide (EGYNVYGIESVKI).
The Ab against the GluA1 subunit was directed against the extracellular domain peptides
(RTSDSRDHTRVDWKR) corresponding to aminoacids 253–267 (271–285 if numbered from
the signal peptide), this region is not conserved in GluA2-4, nor Kainate and NMDAR. GluA1
and GluA2/3 sequences were the same as those reported by Chemicon International. The speci-
ficity of the affinity-purified Abs was previously tested by western blotting studies using cells
transfected and non-transfected with GluA1 and GluA2/3. Our tests do not show crossreactiv-
ity between GluA1 and GluA2/3 Abs, as it has been reported in the specificity tests of Chemi-
con International.
Anti GluN1 (clone 54.1) was from BD Pharmigen, anti GluN2A (clone A3-2D10) was from
Invitrogen, anti-GluN2B (clone N59/20) was from Antibodies Incorporated, anti-tubulin
(clone B-5-1-2) was from Sigma-Aldrich and anti Na/K ATPase was described in [26].
Immunoblotting and densitometric quantification of Western blot bands. The analysis
of the GluR subunits by Western blotting was performed as described previously [27]. In brief,
depending on the target subunit, 2.5, 5, or 10 μg of total homogenates samples were diluted 1:1
(v/v) with Laemmli buffer and then underwent SDS-PAGE using 7.5% acrylamide gel. After
SDS-PAGE, the proteins were electrophoretically transferred to nitrocellulose membranes with
0.45-mm pores (Schleicher and Schull, Dassel, Germany). The blots were blocked overnight in
4% non-fat milk in Tris-buffered saline, washed in a buffer containing 4% nonfat milk and
0.3% Tween 20 in Tris-buffered saline, incubated for 2 h with the primary antibody at the fol-
lowing concentration (GluA1 and GluA2/3: 1–2.5 mg /ml; GluN1 1:1500; GluN2A 1:1000;
GluN2B 1:600; Na/K ATPase 1:1000; tubulin 1:10000) and then incubated for 1h with the
appropriate secondary antibody (anti-rabbit Ly-CorIRDye800RD: 1:10000; anti-mouse Ly-Cor
IRDye680RD: 1:7500). Membranes were further washed in Tris-buffered saline and dried over-
night at RT in darkness. The IR signal was measured through the IR scanner Odyssey CL220x -
Infrared Imaging System.
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The quantification of the signal intensity of the Western blot bands was performed with
iStudio software. The optical density ratio was calculated by taking the optical density of the
control as 100%. The values are the mean ± SEM of 3 replications for each antibody, performed
on 3 separate pools.
Data Analysis
Results are presented as means ± SEM of 6–8 animals/group. Statistical analyses were per-
formed using one-way or two-way ANOVA for parametric results. Follow-up analysis was per-
formed using the Tukey’s test or Bonferroni’s post tests for multiple comparisons, respectively.
T Student test was used for the comparison between two groups. In the case of non-parametric
results, Kruskal-Wallis ANOVA was applied, followed by Dunn’s test.
All the statistical analysis was performed using GraphPad Prism 5 Software (San Diego, CA,
U.S.A) Differences were considered significant at p< 0.05.
Results
Time course of hyperglycemia, mechanical allodynia and PROK2 mRNA
levels in spinal cord after MLD-STZ
As indicated in Fig 1, MLD-STZ induces in animals a rapid hyperglycemic state (panel A) asso-
ciated to the development of allodynia (panel B). On day 14 after MLD-STZ the PWT of dia-
betic mice were reduced compared to controls and remained significantly lower for the entire
period of observation (B).
As depicted in panel C an increase of PROK2 mRNA expression appeared in the spinal cord
of diabetic mice 14 days after the MLD-STZ, corresponding to clear manifestation of allodynic
symptoms and was still significant at day 56.
Modulation of allodynia
A single bolus of PC1 on day 21 after MLD-STZ produced a total recovery in the decreased
PWT of MLD-STZ mice abolishing the established mechanical allodynia in 30 minutes. The
anti-allodynic effect lasted for about 2 hours and gradually disappeared within 4 hours after
PC1 (Fig 2A).
Fig 1. Parallel development of mechanical allodynia and increase of spinal cord PROK2. Time-course of hyperglycemia (A) and mechanical allodynia
(B) after MLD-STZ (80 mg /kg for 3 consecutive days). Data represent mean± SEM of 6 mice per group. Two way ANOVA was used for statistical evaluation,
followed by Bonferroni’s test. ***p<0.001 vs vehicle/CTR. C: time-course of mRNA expression levels of PROK2 in spinal cord (L4-L6) of mice injected with
MLD-STZ. The mRNA levels, determined by Real Time PCR, were expressed in relation to GAPDH and presented as fold-increases over the levels in
vehicle/CTR animals. Data represent mean ±SEM of 6 mice per group. Student T Test was used for statistical evaluation *p<0.05, vs vehicle/CTR.
doi:10.1371/journal.pone.0146259.g001
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The therapeutic administrations of PC1 starting 21 days after STZ for two weeks (i.e. until
35 days after MLD-STZ), was able to effectively alleviate mechanical allodynia. As shown in
Fig 2B the PWT of STZ/PC1 mice were already significantly higher than PWT of STZ/saline
mice after 7 day of treatment and the effect was even more pronounced at the end of 14 day
treatment. Moreover after PC1 suspension the re-appearance of allodynia was delayed: the
PWT remained significantly elevated although progressively decreasing (Fig 2B).
When the PK antagonist was administered in the preventive protocol together with STZ for
two weeks, it significantly prevented the development of allodynia in MLD-STZ mice, as
depicted in Fig 2C.
Since, as reported in Fig 2, PC1 administration in normal animals did never modify PWT in
order to reduce the number of animals, this group was not included in the subsequent
experiments.
Effect of PC1 administration on body weight, glucose and insulin blood
levels
In respect to non-diabetic control animals, a significant body weight loss was observed in dia-
betic mice, and neither therapeutic (Fig 3, panel A) nor preventive (Fig 3, panel D) PC1 treat-
ment did modulate it. Similarly, either therapeutic (panel B) or preventive (panel E) PC1
treatments were not able to modify blood glucose levels in MLD-STZ mice. We also measured
insulin blood levels at the end of a 14 days therapeutic (panel C) or preventive (panel F) treat-
ment with PC1: no significant modulation by the antagonist was ever present.
Effect of PKR antagonist on PROK2, PKR1 and PKR2 mRNA expression
in spinal cord and sciatic nerve
Thirty five days after MLD-STZ, the PROK2 (Fig 4A, a) and PKR2 mRNA levels (A, c) were
higher in spinal cord of diabetic mice than in controls, whereas no significant difference of
PKR1 expression (A, b) was evident.
The PROK2 (panel a) and PKR2 (panel c) up-regulation were significantly reduced by a
therapeutic 14 day PC1 treatment that started on day 21 after diabetes induction. Interestingly
Fig 2. Anti-allodynic effect of PKR antagonist (PC1) administration. Anti-allodynic effect of PC1 administration as a single bolus (A) or as repeated
administrations (B, C). A: acute PC1(s.c. 150 μg/ kg) was administered 21 days after MLD-STZ. B: therapeutic PC1 protocol- PC1 was administered (s.c.
150 μg/ kg, twice-daily) for 14 days, from day 21 to 35 after MLD-STZ. C: preventive PC1 treatment-PC1 was administered (s.c. 150 μg /kg, twice-daily) for 14
days, starting from day 0, time point corresponding to the first STZ administration. Data represent mean± SEM of 6 mice / group. Two way ANOVA was used
for statistical evaluation, followed by Bonferroni’s test. ***p<0.001 vs vehicle/CTR and CTR + PC1; °°p<0.01, °°°p<0.001 vs STZ.
doi:10.1371/journal.pone.0146259.g002
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the spinal cord PROK2 levels were still reduced 21 days after PC1 discontinuation, correspond-
ing to 56 days after MLD-STZ (panel d).
In the preventive protocol, PC1 was administered for 14 days starting at the same moment
of diabetes induction. As reported in panel e, also in this condition PC1 significantly contrasted
PROK2 upregulation.
Thirty five days after MLD-STZ a significant increase of PKR1 mRNA levels was observed
also in sciatic nerve (Fig 4B). Therapeutic PC1 administrations were effective in reducing PKR1
up-regulation to basal in the sciatic nerve. Real-Time PCR analysis for PROK2 and PKR2
mRNA evaluation failed to determine their expression levels in the sciatic nerve (data not
shown).
Spinal cord glutamate receptor modulation by diabetes and preventive
PC1 treatment
As reported in Fig 5, 14 days after MLD-STZ a decrease of the NMDA receptor subunit
GluN2A was present (B), while the expression of the GluN2B subunit significantly increased
(C). Early PC1 administration was effective in preventing GluN2B up-regulation in spinal cord
(C), but did not affect the GluN2A subunit reduction (B). As further control we also checked
for the possible effect of treatments on the expression of other GluR subunits, but we didn’t
find any change in the expression of AMPA receptors containing GluA1 and GluA2/3 subunits
and in the level of the NMDA receptors containing the GluN1 subunit neither after MLD-STZ
nor after preventive PC1 treatment (A, D and E).
Fig 3. PC1 does not affect body weight, blood glucose and insulin levels. Effect of PC1 administration from day 21 to day 35 on body weight (panel A),
blood glucose levels (panel B) and insulin levels (panel C). Plasma insulin levels were measured at the end of the PC1 therapeutic treatment, i.e. on day 35
after MLD-STZ. Effect of preventive PC1 administration (from day 0 to 14) on body weight (panel D), blood glucose levels (panel E) and insulin levels (panel
F). Plasma insulin levels were measured at the end of the PC1 therapeutic treatment, i.e. on day 14 after MLD-STZ. ***p<0.001 vs vehicle; * p<0.05 vs
vehicle
doi:10.1371/journal.pone.0146259.g003
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Effect of therapeutic PKR blocking on cytokine levels in spinal cord and
sciatic nerve
As illustrated in Fig 6, 35 days after MLD-STZ, protein and mRNA levels of IL-1β were
increased in spinal cord (A and C) and in the sciatic nerve (E and G) of diabetic mice.
Fig 4. PROK2 and PKRs are overexpressed in spinal cord and sciatic nerve in diabetic mice, and the PKR antagonist PC1 normalizes them. (A)
PROK2, PKR1, PKR2 mRNA expression in spinal cord (L4-L6), (a)(b)(c) 35 days after diabetes induction with MLD-STZ, at the end of therapeutic PC1
treatment (S.C. 150 μg/ kg, twice-daily from day 21 to 35 after MLD-STZ). (d) PROK2mRNA 56 days after diabetes induction with MLD-STZ, 21 days after
the discontinuation of the therapeutic PC1 treatment; (e)PROK2 mRNA expression 14 days after the initiation of preventive PC1 treatment (s.c. 150 μg/ kg,
twice-daily for 14 days, starting from day 0, time point corresponding to the first STZ administration). B) PROK2mRNA expression in sciatic nerve 35 days
after diabetes induction with MLD-STZ at the end of therapeutic PC1 treatment (s.c. 150 μg/ kg, twice-daily from day 21 to 35 after MLD-STZ). The mRNA
levels, determined by Real Time PCR, were expressed in relation to GAPDH and presented as fold-increases over the levels in CTR animals. Data represent
mean± SEM of 6 mice per group. One way ANOVA was used for statistical evaluation, followed by Tukey’s test for multiple comparisons. *p<0.05, ** p<0.01
vs vehicle, °p<0.05 vs STZ.
doi:10.1371/journal.pone.0146259.g004
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Therapeutic PC1 administrations from day 21 to 35, efficaciously contrasted IL-1β up-regula-
tion both in spinal cord and sciatic nerve.
In spinal cord no modulation of IL-10 protein levels was observed (B). On the contrary, IL-
10 mRNA expression was slightly decreased in MLD-STZ mice and PC1 normalized it (D).
When we evaluated spinal cord IL-1β and IL-10 mRNA 56 days after MLD-STZ, corre-
sponding to 3 weeks after PC1 last treatment, the effect of treatment was still present, although
less evident. In fact both IL-1β (panelC, inset c) and IL-10 (panel D, inset d) levels in PC1
treated MLD-STZ animals were still not different from those of non diabetic mice, although
they were not anymore significantly different fromMLD-STZ.
In sciatic nerve of MLD-STZ mice the protein content and the mRNA of IL-10 were
decreased compared to controls (F and H). As shown in panel H, PC1 administrations led to
IL-10 mRNA production above the physiological levels and this contrasted the decrease of IL-
10 protein (F) induced by MLD-STZ.
Effect of PKR antagonism on peripheral macrophage and splenocyte
cytokines
Thirty five days after MLD-STZ, an alteration of peripheral cytokines was observed. A signifi-
cant increase of IL-1 β production by MLD-STZ macrophages was present, while IL-10 levels
were decreased (Fig 7A, a and b, respectively). PC1 administrations (therapeutic treatment)
were effective in reverting these alterations, re-establishing cytokine balance. In order to assess
the status of the Thelper cytokine balance, we decided to measure the more representative and
prototype cytokines for Th1, i.e. IFN-γ and IL-2, and for Th2, i.e.IL-4 [24]. Moreover we also
evaluated IL-10 production, since this cytokine was shown to be very sensible to PROK2 regu-
lation [15].
In splenocytes, we observed a marked increase of IFN-γ levels (Fig 7B, a) and, even if not
significant, higher concentration of IL-2 (Fig 7B, b). A protective effect induced by PC1 treat-
ment (from day 21 to day 35 after MLD-STZ) was strongly evident on IFN-γ production as
shown in panel a. The production of IL-4 and IL-10 was never altered (7B, panels c and d) in
splenocytes. IFN-γ/IL-4 ratio is frequently used as index for determining T helper profile. As
shown in Fig 6C, PC1 administrations completely prevented the alteration of Th1/Th2 balance
in diabetic mice, where it was significantly shifted towards Th1.
Fig 5. PC1 administration prevents GluN2B overexpression in spinal cord. Effect of preventive PC1
administrations (14 days) on GluN1 (A), GluN2A (B), GluN2B (C), GluA1 (D) and GluA2/3 (E) subunit content
and representative Western blot bands in spinal cord 14 days after MLD-STZ. Levels of glutamate receptor
subunits were normalized on tubulin. Na/K ATPase was used as controls for the integrity of plasma
membrane proteins (F). The values are the mean ± SEM of 3 replications for each antibody, performed on 3
separate pools. *p<0.05,**p<0.01 ***p<0.001 vs vehicle.
doi:10.1371/journal.pone.0146259.g005
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We measured cytokine levels in pancreas of diabetic animals, 35 days after the induction of
the pathology, and we observed a significant decrease of IL-10 level, that was 27.53 ± 3.5 ng /
mg proteins in healthy animals, and was reduced to 10.88 ± 0.64 ng/ mg proteins in diabetic
mice. Therapeutic PC1 treatment prevented IL-10 decrease in the pancreatic tissue
(24.33 ± 5.507 ng/ mg proteins), further sustaining the anti-inflammatory efficacy of the
treatment.
Discussion and Conclusion
In this work we provide evidences about the involvement of the recently discovered chemokine
PROK2 and its receptors PKR1 and PKR2, in diabetic painful neuropathy and in the related
inflammatory events. Our data demonstrate that in diabetic mice spinal cord PROK2 is impli-
cated both in the early stage of allodynia development as well as in its maintenance. Indeed an
over expression of PROK2 in spinal cord was present since the appearance and for all the per-
sistence of allodynia.
The PKRs antagonist PC1 was highly effective in relieving diabetes-induced hypersensitiv-
ity. Repeated administrations of PC1 significantly reduced mechanical allodynia in STZ mice
treated in presence of fully developed neuropathy, while it completely prevented its develop-
ment when given to animals not yet neuropathic. Interestingly the therapeutic schedule delayed
the reappearance of painful symptoms after PC1 suspension, suggesting that blocking PROK2
signalling could induce long lasting changes in the neuronal circuits or in the neuroinflamma-
tory phenomena involved. Moreover, a single acute injection of PC1 rapidly reduced estab-
lished allodynia suggesting a direct action on nociceptor PKRs, whose blockade decreases the
transmission of painful stimuli [12].
The anti-allodynic effect observed after chronic PC1 treatment could be ascribed to its abil-
ity to prevent or reduce the availability of a potent pro-nociceptive/pro-inflammatory agent
such as PROK2 itself in the spinal cord. Therapeutic PC1 administrations reduced or prevented
PROK2 and PKR2 increase in spinal cord of STZ mice. The ability of PC1 to counteract the
PROK2 overexpression seems to be mediated by the PKR1 as it was demonstrated a specific
involvement of this receptor in regulating PROK2 levels during inflammation and in nerve
lesion neuropathic models [12,17,21,28]. In normal and malignant myeloid cell lines a similar
positive loop between PROK2 stimulation of PKR1 and STAT3-mediated PROK2 production
has been described [29,30]. In addition, the prevention of PROK2 up-regulation in the spinal
cord was long lasting and persisted after suspension of PC1. We previously showed in the CCI
injury model that PROK2 is up-regulated in spinal cord astrocytes and primary sensory neu-
rons [12] and it may activate the PKR2 expressed in spinal cord neurons and overexpressed
after injury. The observation that in mice precociously treated with PC1 allodynia did not
develop, led us to hypothesize that when PC1 treatment started on day 0, i.e. when the plasticity
of the central nervous system that underlies allodynia had not yet established [31], the blocking
of PKR2 and PROK2 synthesis in spinal cord may prevent or slow down this neuronal
plasticity.
Fig 6. PKR antagonist PC1 restores a correct pro-anti-inflammatory cytokine balance in spinal cord and sciatic nerve. Effect of therapeutic PC1
administrations on cytokines levels in spinal cord and sciatic nerve. IL-1β (A, C, E and G) and IL-10 (B, D, F and H) protein content and mRNA expression in
spinal cord and sciatic nerve 35 days after diabetes induction with MLD-STZ, at the end of therapeutic treatment with PC1 (s.c. 150 μg/ kg, twice-daily for 14
days starting on day 21 from the first STZ injection). Cytokine protein content, evaluated by ELISA, was reported as pg cytokine/ mg total proteins (A, B, E
and F). Cytokine mRNA levels, determined by Real Time PCR, were expressed in relation to GAPDH and presented as fold-increase over the levels in
vehicle/CTR animals (C, D, G and H). Inset c and d: expression levels of IL-1β (inset c) and IL-10 (inset d) evaluated 56 days after STZ, corresponding to 3
weeks after last PC1 injection. Data represent mean ±SEM of 6–8 mice per group. One way ANOVA was used for statistical evaluation, followed by Tukey’s
test for multiple comparisons. *p<0.05, ** p<0.01, ***p<0.001 vs vehicle; °p<0.05, °°p<0.01, °°°p<0.001 vs STZ.
doi:10.1371/journal.pone.0146259.g006
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In order to specifically evaluate the effect of PKR antagonism on neuronal sensitisation, we
evaluated its effect on glutamatergic receptors in spinal cord, that are hyperactivated in diabetic
animals [32,33].
Evidences indicate that alterations in synaptic transmission are associated to NP, including
phosphorylation of NMDA receptors, altered NMDA receptor subunit expression pattern and
increased NMDA-mediated current [34,35]. Nociceptive hypersensitivity induced by periph-
eral injury or tissue inflammation is known to be mediated by the activation of GluN2B con-
taining NMDAR distributed in spinal cord dorsal horns [36–38]. Moreover, Iwata et al. [39]
demonstrated that in spinal neurons the expression of GluN2A decreased while that of
GluN2B increased after peripheral nerve injury. Consistently, we demonstrate that in presence
of fully developed mechanical allodynia a decrease of the spinal NMDAR subunit GluN2A was
present, while the expression of the GluN2B is increased. Early PC1 administrations were effec-
tive in preventing GluN2B up-regulation in spinal cord of diabetic mice, and this effect may
contribute to the observed allodynia reduction. Interestingly in an in vitro model of cerebral
injury, glutamate induced PROK2 expression in cortical neurons through NMDA receptor
activation [40], suggesting a positive loop between PROK2, glutamate and NMDA, that could
be reduced by antagonising PKR activation with the antagonist.
An important contribution to the antiallodynic activity of PC1 may also be ascribed to the
relevant role that the prokineticin system plays in modulating peripheral immune/inflamma-
tory reactions and neuroinflammation. We demonstrated that PC1 treatment significantly
reduced IL-1β overexpression while enhancing IL-10 mRNA in the spinal cord in STZ mice.
As we had previously reported for the CCI model [12,16], it can be suggested that by reducing
PROK2 and PKR2 levels in spinal cord, the signalling leading to IL-1β production is signifi-
cantly blunted. We are aware that in the present work we did not characterize the cellular
source of the cytokines in the spinal cord. However both microglia and astrocytes have been
indicated as the main cells responsible for cytokine production [41,42]. Interestingly we previ-
ously demonstrated that both PKRs and PROK2 are extensively expressed in astrocytes, where
they appear upregulated in the chronic constriction injury model [12], suggesting the relevance
of these cells in prokineticin-induced cytokine modulation.
When we analysed IL-1β and IL-10 56 days after diabetic induction, they were still signifi-
cantly altered, consistently with the presence of allodynia. Interestingly the effect of PC1 on the
levels of these cytokines started to subside 3 weeks after its suspension but did not completely
disappeared, since IL-10 levels remained upregulated in the PC1 group, IL-1β upregulation
was still reduced, although at a lesser extent, and also PROK levels were still slightly decreased.
At this time point a mild anti-allodynic effect is still present, indicating a possible correlation
with the neuroinflammatory markers. In future experiments we plan to follow the system also
for a longer time.
We are aware that other proinflammatory cytokines, such as TNF-α or IL-6, have also been
involved in spinal pain modulation [6,8]. However in our preview work [5,7] we measured
only a transient short lasting alteration of TNF in spinal cord of neuropathic animals, while IL-
1β appeared the proinflammatory cytokines more stably overexpressed for a long period of
Fig 7. Effects of therapeutic PC1 administrations on cytokine production bymacrophage and splenocytes. (A) Effect of therapeutic PC1
administrations (s.c. 150 μg/ kg, twice-daily for 14 days from day 21 to 35 after MLD-STZ) on IL-1β (a) and IL-10 (b) production by peritoneal macrophages.
Data represent mean± SEM of 6–8 mice per group. (B) Effect of therapeutic PC1 administrations (s.c. 150 μg/ kg, twice-daily for 14 days from day 21 to 35
after MLD-STZ) on IFN-γ (a), IL-2 (b), IL-4 (c) and IL-10 (d) production by splenocytes. (C) Splenocyte Th1/Th2 profile was expressed as IFN-γ/IL-4 ratio and
calculated by setting IFN-γ/IL-4 ratio of the control as 100%. Cytokine content, evaluated by ELISA, was reported as protein concentrations in culture media.
Data represent mean ±SEM of 6 mice per group. One way ANOVA was used for statistical evaluation, followed by Tukey’s test for multiple comparisons.
*p<0.05 vs vehicle/ CTR; °p<0.05 vs STZ.
doi:10.1371/journal.pone.0146259.g007
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time in spinal cord in the presence of neuropathic pain [5,7]; for this reason we focussed on
this proinflammatory cytokine.
From our data, it also emerges a control of PROK2 on the balance of pro- and anti-inflam-
matory cytokines in the sciatic nerve. In the diabetic nerve, Schwann cells, resident and macro-
phages recruited from bloodstream present a clear pro-inflammatory phenotype, characterized
by high IL-1β and low IL-10 levels [7,43]. The antagonism with PC1 was efficacious in revert-
ing this pro-inflammatory phenotype. Indeed we measured extremely high levels of sciatic
nerve IL-10, suggesting that the block of PKRs drives nerve macrophages towards an anti-
inflammatory direction. In previous work from our group in the CCI neuropathic model, we
demonstrated that although IL-1β and IL-10 are the more affected cytokines after PC1 treat-
ment, we also observed a minor modulation of other cytokines such as TNF and IL-17 in the
nerve [16]. Although we did not specifically measure them in this work, it is possible that other
cytokines may be involved in the sciatic nerve.
The augmentation of PKR1 mRNA expression in the nerve could be attributed to infiltrating
inflammatory cells expressing this receptor. Since PKR1 is the most implicated in the immune
response and mediates macrophage chemotaxis [14], it can be assumed that its blocking with
PC1 could affect macrophage migration, reducing the recruitment of further inflammatory
cells expressing PKR1. These data are in agreement with the relevance of peripheral mono-
cytes/macrophages recruitment recently reported in the generation of neuropathic pain in a
chemotherapy-induced neuropathy model [44].
Inflammation and immune activation have been recognized as fundamental mechanisms in
the pathophysiology of diabetes and of its complications [45]. An autoimmune reactivity char-
acterized by a T helper 1 profile [45,46] is consistently present in diabetes, and elevated pro-
inflammatory cytokines, such as IFN-γ, TNF-α, and IL-1β [46–48] also participate in pancre-
atic beta-cells destruction. In agreement with the potent immunomodulatory activity of
PROK2 [14,15,49,50], we now demonstrate that PROK2 and PKRs are involved also in modu-
lating the peripheral immune response in the STZ model. PC1 treatment reduced the periph-
eral inflammatory status, decreasing macrophage IL-1β and maintaining Th1/Th2 balance.
Interestingly, the block of PKRs was also able to prevent IL-10 alteration in pancreas. Up to
now we do not know whether this effect is mediated by PKRs that have been shown to be pres-
ent on pancreatic tissues [51–53] or depends on the general peripheral immunomodulation
achieved with PC1.
Therefore we hypothesize that PROK2 may be involved in the several inflammatory pro-
cesses that take place in diabetes. If this hypothesis is true, the blocking of PKRs could have
beneficial effects on other diabetic complications, such as retinopathy and nephropathy [54].
Although PC1 blocked the STZ-induced allodynia, neuroinflammation and peripheral
immune activation, it did not affect hyperglycaemia nor plasma insulin levels. However this is
not uncommon, since other compounds, such as cannabis extracts, buprenorphine and ghrelin,
have beneficial action on diabetic alterations and tissue damage without affecting STZ-induced
hyperglycaemia [55–57]
In conclusion, we suggest the PK system as a promising target for novel pharmacological
approaches to treat diabetes complications such as painful neuropathy.
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